Sponsor

Dendreon

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Dendreon appears in 29 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials29
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

29 shown
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-TNCT06134232 · lead sponsor · 2023-10-02
RECRUITING
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate CancerNCT03686683 · lead sponsor · 2018-10-18
COMPLETED
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate CancerNCT01981122 · lead sponsor · 2013-09-01
COMPLETED
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-TNCT01727154 · lead sponsor · 2012-10-01
TERMINATED
Sipuleucel-T Manufacturing Demonstration StudyNCT01477749 · lead sponsor · 2012-06-01
COMPLETED
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate CancerNCT01981109 · lead sponsor · 2012-01-01
TERMINATED
Sipuleucel-T in Metastatic Castrate Resistant Prostate CancerNCT01338012 · lead sponsor · 2011-12-01
TERMINATED
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate CancerNCT01487863 · lead sponsor · 2011-12-01
COMPLETED
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate CancerNCT01431391 · lead sponsor · 2011-09-01
COMPLETED
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate CancerNCT01306890 · lead sponsor · 2011-01-27
COMPLETED
Open Label Study of Sipuleucel-T in Metastatic Prostate CancerNCT00901342 · lead sponsor · 2009-10-01
COMPLETED
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) AntigenNCT00715078 · lead sponsor · 2008-10-01
COMPLETED
Sipuleucel-T as Neoadjuvant Treatment in Prostate CancerNCT00715104 · lead sponsor · 2008-07-01
COMPLETED
Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)NCT00849290 · lead sponsor · 2004-04-01
COMPLETED
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone TherapyNCT00065442 · lead sponsor · 2003-07-01
COMPLETED
PROvenge Treatment and Early Cancer TreatmentNCT00779402 · lead sponsor · 2001-10-01
COMPLETED
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate CancerNCT01133704 · lead sponsor · 2000-05-01
COMPLETED
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyNCT00005947 · lead sponsor · 1999-11-01
COMPLETED
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCNCT06100705 · collaborator · 2023-12-20
RECRUITING
Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate CancerNCT07756593 · collaborator · 2026-11-30
NOT_YET_RECRUITING
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate CancerNCT05806814 · collaborator · 2023-11-12
ACTIVE_NOT_RECRUITING
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate CancerNCT05751941 · collaborator · 2023-02-14
ACTIVE_NOT_RECRUITING
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate CancerNCT03024216 · collaborator · 2017-02-06
COMPLETED
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPCNCT02463799 · collaborator · 2016-02-22
COMPLETED
A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-TNCT02232230 · collaborator · 2014-06-01
COMPLETED
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate CancerNCT01804465 · collaborator · 2014-04-22
COMPLETED
PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate CancerNCT02042053 · collaborator · 2014-01-01
TERMINATED
Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-TNCT01833208 · collaborator · 2013-07-03
COMPLETED
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate CancerNCT01706458 · collaborator · 2013-05-20
COMPLETED

Drugs studied in this sponsor's trials

10 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Dendreon as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
sipuleucel-T3
enzalutamide2
abiraterone1
abiraterone acetate1
apalutamide1
ipilimumab1
leuprolide acetate1
Provenge1
sipuleucel-T RxCUI 997261 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 3 trials enzalutamide RxCUI 1307298 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials abiraterone RxCUI 1100072 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial abiraterone acetate RxCUI 1100071 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial apalutamide RxCUI 1999574 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial ipilimumab RxCUI 1094833 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial leuprolide acetate RxCUI 203217 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial Provenge RxCUI 978086 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial sipuleucel-T Injection RxCUI 1726181 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial testosterone cypionate RxCUI 835827 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial

Sponsor roles

lead sponsor18
collaborator11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.